Verve Therapeutics Inc (VERV)

33.15 -2.59  -7.25% NASDAQ Nov 26, 16:00 USD

Verve Therapeutics Free Cash Flow (Quarterly):

-22.36M for Sept. 30, 2021
View 4,000+ financial data types
Browse...
View Full Chart

Free Cash Flow (Quarterly) Chart

Export Data
Save Image
Print Image

Historical Free Cash Flow (Quarterly) Data

View and export this data going back to 2020. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
Sept. 30, 2021 -22.36M
June 30, 2021 -14.65M
March 31, 2021 -16.21M
Dec. 31, 2020 -15.93M
   
Sept. 30, 2020 -7.346M
June 30, 2020 -7.54M
March 31, 2020 -7.875M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

Advertisement

Free Cash Flow Definition

Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.

Read full definition.

Free Cash Flow (Quarterly) Benchmarks

Regenxbio Inc -55.06M
Krystal Biotech Inc -28.25M
Beam Therapeutics Inc -2.773M

Free Cash Flow (Quarterly) Range, Past 5 Years

Minimum -22.36M Sep 2021
Maximum -7.346M Sep 2020
Average -13.13M

News

Verve Therapeutics' Q3 Net Loss Shrinks
MT Newswires 11/10 07:51 ET
Top IPO additions to Russell 2000 Index
SA Breaking News 09/17 10:48 ET
WHO urges fair access to gene-editing technologies
SA Breaking News 07/12 11:51 ET
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.